Clinical Trial

A Clinical Study in Healthy Adults to See How the Body Processes and How Safe a Tablet That Combines Gemigliptin, Dapagliflozin, and Metformin is, Compared With Taking Zemiglo and Xigduo XR Together While Fasting.

Completed Phase 1
View on ClinicalTrials.gov →
Summary
Bioequivalence study for the fixed-dose combination of Gemigliptin/Dapagliflozin/Metformin 50/10/1000 mg under fasting conditions in healthy volunteers
Protocol Amendment History 1 change
critical Trial completed 2026-07-25
Trial Details
NCT Number NCT07399470
Lead Sponsor LG Chem
Conditions Healthy Volunteers, Fasting Conditions
Enrollment 58 participants
Start Date 2026-01-09
Primary Completion 2026-02-06 (estimated)
Study Completion 2026-02-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-24